BREAKOUT STOCK ALERT
ECOR - electroCore, Inc. - Common Stock
Initial Alert Price: $2.26
Potential Price: $3.3
Potential Gains: 46.02
Stop Loss Limit: $
Re-Entry Trade Alert:
ECOR is currently trading at the bottom of it's long-term trend line providing the opportunity to re-enter into the trade and retest the $3.30 Levels for a potential 40-45% Swing Trade over the next few weeks.
The company announced on Feb. 24th that the completion of patient enrollment in SAVIOR-1, or "Prospective, Randomized, Controlled Study to Evaluate the Effect of Non-Invasive Electrical Vagus Nerve Stimulation on Respiratory Symptoms due to COVID-19."
The company also announced the Australian Government Department of Health approved the company's GammaCore Migraine Therapy Vagus Nerve Electrical Simulator.
From a fundamental long-term outlook, the company is showing 24% EPS YoY and +197% Growth in Net Profit Margin YoY. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
ECOR - electroCore, Inc. - Common StockInitial Alert Price: $2.26
Potential Price: $3.3
Potential Gains: 46.02
Stop Loss Limit: $
Re-Entry Trade Alert:
ECOR is currently trading at the bottom of it's long-term trend line providing the opportunity to re-enter into the trade and retest the $3.30 Levels for a potential 40-45% Swing Trade over the next few weeks.
The company announced on Feb. 24th that the completion of patient enrollment in SAVIOR-1, or "Prospective, Randomized, Controlled Study to Evaluate the Effect of Non-Invasive Electrical Vagus Nerve Stimulation on Respiratory Symptoms due to COVID-19."
The company also announced the Australian Government Department of Health approved the company's GammaCore Migraine Therapy Vagus Nerve Electrical Simulator.
From a fundamental long-term outlook, the company is showing 24% EPS YoY and +197% Growth in Net Profit Margin YoY. #Breakout #Stocks #Trading #Investing #Alerts #StockMarket #Daily #News #Today
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penerbitan berkaitan
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.